ETX.L Share News (ETX)

ETX.L Information

There is currently no data for ETX

E-Therapeutics and C4X upbeat on Parkinson's collaboration

Thu, 06th Dec 2018 16:04

(Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the potential treatment of Parkinson's Disease (PD).The two AIM-traded firm described PD as a progressive neurological disease which affected up to 10 million people worldwide, with incidence increasing as the global population aged.They said that, while to date some PD drivers had been identified, it had not resulted in any novel therapies.C4X's proprietary genetic target discovery technology 'Taxonomy3' had found multiple novel disease-associated genes in Parkinson's Disease (PD), in addition to identifying discrete patient subgroups that could potentially provide an opportunity in stratified medicine, the companies said.It was estimated that selecting genetically-supported drug targets should double the success rate of investigational new drugs in clinical development.Those genetic discoveries provided a "significant opportunity" to uncover biological processes central to the causation and progression of disease.E-therapeutics' proprietary 'Network-Driven Drug Discovery' (NDD) approach was applied to the unique dataset, with the study analysing approximately 200 PD-associated genes identified by C4X's Taxonomy3 genomics platform.Initial results identified novel potential pathophysiological mechanisms relevant to PD, as well as highlighting known mechanisms, the companies claimed.They said the implications of such insights were now being explored further, and suggested a number of novel intervention strategies that could be taken forward using ETX's NDD approach, as well as providing another basis on which to select targets derived directly from C4X's Taxonomy3 platform.Ultimately, the approach could yield new drugs to treat the disease, C4X and e-Therapeutics said."The initial results from this collaboration highlight the critical importance of considering biology in a network context to gain insights into clinically relevant biological mechanisms in complex disease," said e-Therapeutics head of discovery biology Alan Whitmore."The ability to link genetic data to disease mechanism remains one of the greatest challenges of our industry."Whitmore said that, by using the advanced computational analytics of the NDD platform, the company was able to confirm the centrality of a number of known mechanisms in PD and, importantly, identify potential new ones."This in turn, opens up the prospect of new approaches to the discovery of effective novel drugs to tackle this and other undertreated, debilitating conditions."Craig Fox, chief scientific officer at C4X, added that following the identification of novel drug targets for the treatment of PD from the direct findings from the Taxonomy3 platform, the company recognised there still remained "untapped potential" in the proprietary analysis."By working with the team at e-Therapeutics and utilising their NDD platform, we have been able to access cutting-edge mathematical and data analysis techniques to augment and interrogate the vast amount of biological information currently available in both public and private databases."This combination has identified additional novel biological pathways for the treatment of PD and we look forward to moving these findings forward to initiate new drug discovery programmes."

More News

16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Latest Share Chat

ETX.L Share News (ETX)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

E-Therapeutics and C4X upbeat on Parkinson's collaboration

Login to your account

Quickpicks are a member only feature

Login to your account